本文選題：肺癌　切入點：免疫細胞治療　出處：《中國腫瘤生物治療雜志》2017年05期

【摘要】：目的:應(yīng)用多因子固相抗體芯片篩選免疫細胞治療肺癌患者血清的標(biāo)志性蛋白作為臨床評價指標(biāo),建立肺癌療效評價模型。方法:采用多因子Proteome Profiler~(TM)固相抗體芯片和Image J軟件對5例肺癌惡化患者(惡化組)、5例肺癌治療有效患者(有效組)及10例健康體檢者(正常個體對照組)進行血清蛋白的灰度/光密度分析,將得到的蛋白灰度值采用SPSS軟件進行分析,建立肺癌療效評價的Fisher模型。結(jié)果 :對比肺癌治療惡化組、有效組患者和正常對照組健康個體的共有標(biāo)志性蛋白,篩選得到8個有顯著差異(P0.05)的蛋白(二肽基肽酶Ⅳ、生長激素、IL-4、髓過氧化物酶、骨橋蛋白、晚期糖基化終產(chǎn)物受體、腫瘤壞死因子-α和尿激酶纖維蛋白溶酶原激活物受體)。對所有試驗者進行聚類分析,發(fā)現(xiàn)這8個蛋白能區(qū)分惡化組和有效組患者及正常組健康個體。肺癌的Fisher模型得到驗證。結(jié)論:多因子固相抗體芯片技術(shù)和優(yōu)化統(tǒng)計方法能夠篩選出與肺癌的發(fā)生發(fā)展及療效有關(guān)的血清生物標(biāo)志物,為肺癌的發(fā)病機制研究及臨床診斷和治療奠定一定的臨床試驗基礎(chǔ),對肺癌的個體化治療具有重要指導(dǎo)意義。
[Abstract]:Objective: to establish a model for evaluating the efficacy of lung cancer by using multifactor solid phase antibody chip to screen the iconic protein in serum of patients with lung cancer.Methods: using multifactor Proteome Profiler TM solid phase antibody chip and Image J software, 5 patients with lung cancer deterioration (5 patients with lung cancer effective treatment) and 10 healthy people (normal individual control group) were treated with serum.Gray / optical density analysis of protein,The gray value of protein was analyzed by SPSS software, and the Fisher model of lung cancer curative effect evaluation was established.Results: compared with the control group and the effective group, eight proteins (dipeptidyl peptidase 鈪，

本文編號：1713427